by Mark Curtis | Oct 9, 2014
Welcome to your deal review for the month of September. There was some healthy news flow around cell-based immunotherapy companies this past month, heating up a space that is already ablaze with activity. Undoubtedly the company that took the spotlight was...
by David Brindley | Oct 1, 2014
. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. There were two momentous events on the night of August 23, 2014. First, the inaugural...
by David Brindley | Sep 23, 2014
. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. Assume a single bacterium weighs one thousand billionth of a gram. If it, and each of its...
by Mark Curtis | Sep 18, 2014
. Welcome to your Update from the Clinic for the month of August. Asterias Biotherapeutics breathes new life into a cell therapy shelved two years ago and initiates a Phase I/II study in patients with spinal cord injury. Northwest Biotherapeutics provides an update on...
by David Brindley | Sep 16, 2014
. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. Consider this question: if I gave you the option to take a drug offering a 100 percent chance...
by Mark Curtis | Sep 11, 2014
. Welcome to your deal review for the month of August. As would be expected at the end of the summer news flow was modest, but Northwest Biotherapeutics kept things alive with a $17.5 million financing via convertible debt, while Gamida Cell announced a game-changing...
Comments